Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Doximity

Doximity, Inc. develops an online healthcare resource and interactive platform. The Company cloud-based platform enables its members to collaborate with their colleagues, securely coordinate patient care, and conducts virtual patient visits. Doximity serves customers in the United States.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Doximity surpasses Q4 revenue expectations and eyes continued growth

Doximity's Q4 2023 performance exceeded expectations, showcasing strong financial metrics and strategic investments. The company's outlook for Q1 2024 indicates continued growth, with a focus on topline expansion and product innovation. While facing challenges in pricing strategies and competitive landscape, Doximity is well-positioned to capitalize on opportunities in the healthcare technology sector.

Doximity reports strong Q1 results but lowers 2024 guidance

Doximity delivered strong financial performance in Q1, but challenges in upsell close rates led to a downward revision in annual guidance. The company's focus on innovation, expansion, and shareholder value, along with a cautious outlook for the remainder of the year, presents a mixed picture of opportunities and challenges for investors.

Doximity reports strong Q3 earnings, eyes growth amid product challenges

Doximity's Q3 performance demonstrated resilience and growth potential despite challenges in meeting annual guidance due to product delays.
The company's focus on innovation, strong client relationships, and strategic investments position it well for future growth and market leadership.
With a commitment to R&D, expanding product offerings, and maintaining pricing discipline, Doximity aims to capitalize on opportunities and navigate challenges for sustained success.

Doximity surpasses Q4 revenue targets, poised for growth and innovation

Doximity's Q4 performance exceeded expectations, with robust revenue growth, strong margins, and strategic investments in new products and talent.
While facing challenges like flat growth in certain segments and pricing adjustments, the company is well-positioned to capitalize on opportunities in network expansion and technology innovation.
With a focus on enhancing user experience, driving engagement, and optimizing revenue streams, Doximity is poised for continued success and value creation for shareholders.
The company's financial health, innovative product offerings, and market positioning indicate a promising outlook for sustained growth and competitive advantage in the healthcare technology sector.

Doximity surpasses Q1 revenue expectations, faces upsell challenges

Doximity's Q1 performance was strong, but challenges in upsells prompted a staff reduction and revised guidance. The company is optimistic about long-term growth, leveraging new products and a self-serve ad platform for future success.

Doximity beats Q2 expectations, eyes growth amidst market uncertainties

Doximity's strong Q2 performance exceeded revenue and EBITDA guidance, driven by record physician engagement and new product success.
While facing market uncertainties and competition challenges, the company sees opportunities in pricing strategies and continued growth.
Investments in high-touch services, Telehealth, and video products are paying off, with a focus on enhancing client offerings.
Integration with IQVIA for real-time ROI analysis positions Doximity for future growth and client value creation.

Doximity beats Q3 revenue, eyes growth through AI products

Doximity's Q3 performance exceeded expectations with strong revenue and margin growth. The company faces challenges with elongated sales cycles but has opportunities for growth through AI products and new modules. Overall, Doximity's competitive position remains strong in the market.

Doximity exceeds Q4 revenue, eyes mid-teens growth post-COVID

Doximity's Q4 earnings call highlighted strong financial performance, customer satisfaction initiatives, and growth opportunities in digital marketing and new business segments. While facing challenges in growth slowdowns and market uncertainties, the company is leveraging strengths in optimized margins, visibility into revenue guidance, and customer commitment to drive future success.

Doximity excels in Q1 2025, driving growth through client value

Doximity's Q1 2025 performance reflects strong revenue growth, operational efficiency, and client value proposition.
The company's focus on innovation, customer engagement, and strategic insights positions it well for sustained growth.
Despite challenges, Doximity's proactive approach to industry dynamics and growth opportunities bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Doximity recently reported strong financial results. The company has solid growth opportunities.

Should You Buy This Stock After It Skyrocketed by 33%?

Doximity's guidance in no way reflects the positive tea leaves management discussed during the conference call. Doximity reported better than expected Q1 results with revenues of $127 million and adjusted EBITDA of $66 million, leading to a 39% increase in share price. The company minimally increased its adjusted EBITDA forecast for FY '25, but potential for sustainable growth rates is not reflected in consensus estimates.

Reconsidering Doximity Shares: Should Investors Bet On A Sustained Revenue Growth Inflection

Doximity Inc. NASDAQ: DOCS is a digital professional medical networking platform that is a cross between LinkedIn and Meta Platforms Inc. NASDAQ: META Facebook. The platform enables physicians to connect with their colleagues to collaborate on patient treatments and research.

Doximity: The 'Facebook for Doctors' Surges After Earnings Beat

Life Time Group Holdings

Investors with an interest in Medical Services stocks have likely encountered both Life Time Group Holdings, Inc. (LTH) and Doximity (DOCS). But which of these two stocks is more attractive to value investors?

LTH vs. DOCS: Which Stock Should Value Investors Buy Now?

Revenue of $126.7 million exceeded management's expectations. Adjusted EBITDA of $65.9 million was significantly above guidance.

Doximity: Q1 Revenue, Net Income Soar

Doximity reported strong Q1 FY25 earnings with revenue and Adjusted EBITDA growing 17% and 41% YoY respectively, beating estimates. It saw a 16% increase in customer count in its $500K+ Subscription revenue cohort, while usage of its products continued to grow steadily, alongside expanding margins. Although the management sounded cautious on the state of the economy, it believes that its product innovation should help it capture larger pharma budgets in the coming years.

Doximity: Q1 Earnings Mark A Possible Turnaround For The Company (Rating Upgrade)

Doximity beat estimates on the top and bottom lines. The company continues to report strong margins.

Why Doximity Stock Was Soaring Today

Doximity (NYSE: DOCS ) stock is rising higher on Friday following the release of the medical cloud-based digital platform company's earnings report for its fiscal first quarter of 2025. That earnings report starts off strong with adjusted EPS of 28 cents per share.

Why Is Doximity (DOCS) Stock Up 30% Today?

The medical platform's quarterly result beat expectations on both top and bottom lines, and is also leveraging AI to appeal to customers.

Doximity Stock Jumps 31%. Here's Why.

Start Time: 17:00 January 1, 0000 5:50 PM ET Doximity, Inc. (NYSE:DOCS ) Q1 2025 Earnings Conference Call August 08, 2024, 17:00 PM ET Company Participants Jeff Tangney - Co-founder and CEO Nate Gross - Co-founder and CSO Anna Bryson - CFO Perry Gold - VP of IR Conference Call Participants Brian Peterson - Raymond James Scott Berg - Needham & Company Stephanie Davis - Barclays Jared Hass - William Blair John Pinney - Canaccord Genuity Allen Lutz - Bank of America Elizabeth Anderson - Evercore ISI Jessica Tassan - Piper Sandler Michael Cherny - Leerink Partners Craig Hettenbach - Morgan Stanley Jenny Cao - Truist Securities Stan Berenshteyn - Wells Fargo Securities Jenny Shen - BTIG Operator Good day, everyone, and welcome to the Doximity Fiscal First Quarter 2025 Earnings Call. At this time, I would like to hand things over to Vice President of Investor Relations, Perry Gold.

Doximity, Inc. (DOCS) Q1 2025 Earnings Call Transcript

Doximity (DOCS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.19 per share a year ago.

Doximity (DOCS) Q1 Earnings and Revenues Surpass Estimates

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 first quarter ended June 30, 2024. “We were pleased to deliver strong profits and record engagement last quarter, as we beat on both our top and bottom lines,” said Jeff Tangney, co-founder and CEO of Doximity. “Last quarter, a record 590,000 unique providers used our AI, telehealth, messaging, and scheduling workflow tools to save.

Doximity Announces Fiscal 2025 First Quarter Financial Results

Beyond analysts' top -and-bottom-line estimates for Doximity (DOCS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Gear Up for Doximity (DOCS) Q1 Earnings: Wall Street Estimates for Key Metrics

Doximity (DOCS) closed the most recent trading day at $28.66, moving +1.49% from the previous trading session.

Why the Market Dipped But Doximity (DOCS) Gained Today

ICON

Organon & Co

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ICLR, OGN and DOCS are set to gain the most.

3 Medical Services Industry Stocks to Buy as Healthcare Wage Increases

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2024 after market close on August 8, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before.

Doximity to Release Fiscal 2025 First Quarter Results on August 8, 2024

Doximity (DOCS) closed the most recent trading day at $27.97, moving +0.5% from the previous trading session.

Doximity (DOCS) Ascends While Market Falls: Some Facts to Note

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCS

LOS ANGELES--(BUSINESS WIRE)--DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").

FINAL DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important June 17, 2024 lead plaintiff deadline.

DOCS DEADLINE MONDAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important June 17 Deadline in Securities Class Action – DOCS

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 17, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On August 8, 2023, Doximity released its first quarter fiscal ye.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Doximity, Inc. (DOCS)

RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) (“Doximity” or the “Company”) on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action, captioned Kissler v. Doximity, Inc., et al., Case No. 3:24-cv-02281-JST was filed in the United States District Court for the Northern District of California.

DOCS Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Doximity, Inc. (DOCS) Investors of Filing Deadline in Class Action Lawsuit

LOS ANGELES , June 13, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS).

DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

News for Doximity Stock (DOCS)